Gianni, Luca
Colleoni, Marco
Bisagni, Giancarlo
Mansutti, Mauro
Zamagni, Claudio
Del Mastro, Lucia http://orcid.org/0000-0002-9546-5841
Zambelli, Stefania
Bianchini, Giampaolo http://orcid.org/0000-0002-6790-6267
Frassoldati, Antonio http://orcid.org/0000-0003-3487-3259
Maffeis, Ilaria
Valagussa, Pinuccia
Viale, Giuseppe
Funding for this research was provided by:
Unrestricted grant from Pfizer Italia S.r.l. and from Roche S.p.a. Italy. This work has been also supported in part by a Breast Cancer Research Foundation grant to Luca Gianni.
Article History
Received: 15 June 2021
Accepted: 6 December 2021
First Online: 10 January 2022
Competing interests
: L.G. has been an Advisory Board member and/or consultant for ADC Therapeutics, AstraZeneca, Celgene, Eli Lilly, G1 Therapeutics, Genentech, Genomic Health, Merck Sharp & Dohme, Oncolytics Biotech, Odonate Therapeutics, Onkaido Therapeutics, Roche, Pfizer, Taiho Pharmaceutical, Hexal Sandoz, Seattle Genetics, Synthon, Zymeworks, Sanofi-Aventis, Forty Seven (CD47), GENENTA, METIS Precision Medicine, Synaffix, Menarini Ricerche, Amgen, Biomedical Insights Inc., and a Research Grant from Revolution Medicines to his institution outside the submitted work. M.C. has been an Advisory Board member for AstraZeneca, Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology and Celldex, received honoraria from Novartis, and Research Grant from Roche to his institution outside the submitted work. M.M. reports personal fees from Novartis, Roche, Celgene, Eisai, AstraZeneca, Pfizer, Eli Lilly and MSD Italia outside the submitted work. C.Z. has been an Advisory Board member for Roche, Eisai, Novartis, AstraZeneca, Pfizer, PharmaMar, Amgen, Tesaro, Lilly, Celgene, personal fee from Pierre Fabre and Istituto Gentili, and Research Grants from Roche, Novartis, AstraZeneca, Pfizer, Seattle Genetics, Tesaro, Pierre Fabre, Istituto Gentili, Takeda, TEVA, Medivation, AbbVie, Array BioPharma, Morphotek and Synthon to his institution outside the submitted work. L.D.M. reports personal fees from Roche, Novartis, Pfizer, Ipsen, Takeda, Eli Lilly, Amgen, Daiichi Sankyo, Seagen, Genomic Health, Exact sciences, MSD, AstraZeneca and non-financial support from Celgene, Pfizer, Roche, outside the submitted work. G.B. has been an Advisory Board, consultant or received personal fees from Roche, Pfizer, AstraZeneca, Lilly, Novartis, Neopharm, Amgen, MSD, Chugai, Sanofi, Daiichi Sankyo, EISAI, Genomic Health. A.F. reports personal fees and non-financial support from Roche, Novartis, AstraZeneca, Pfizer, Eli Lilly, Daichii and Seagen outside the submitted work. G.V. reports personal fees from Roche, MSD, BMS, AstraZeneca, Celgene, Dako and personal fees da Daichii Sankyo outside the submitted work. The other authors have no conflicts of interest to declare.